Ribera buys Cialab, a leading laboratory for biological and genetic analysis consolidating its diversification.

With more than 20 years of experience in hospital management, the healthcare Group creates a laboratory division with Ribera LAB and confirms its commitment to growth in the social healthcare sector

The purchase of one of the main laboratories in the Valencian Community adds another asset to the group, after the recent acquisition of Hospital Polusa, in Lugo

Valencia, December 22, 2020. – The Ribera Health Group has signed the acquisition of the Immunological Center of Alicante, Cialab, specialized in biological diagnosis and clinical follow-up through the performance of clinical, genetic analysis, pathological anatomy, microbiology and biopathology, among others. With this acquisition, the Group consolidates its diversification policy and reaffirms its commitment to growth and diversification of services in the social and healthcare sector. Last November, Ribera bought the Polusa Hospital, in Lugo.

The Group has also created a laboratory division called Ribera LAB, which will coordinate the strategy, infrastructures and personnel specialized in clinical and genetic analysis for the entire company. With more than 20 years of experience in health management, seven hospitals, more than 100 Primary Care centers, a FutuRS technological subsidiary, a purchasing center and the management of the Central Clinical Laboratory of Madrid, Ribera adds with its new leading laboratory another important asset which will employ 40 professionals and a wide portfolio of services to support the Group’s health centers.

Cialab, located in Alicante, boasts a Genetics laboratory (for constitutional , prenatal and oncohematological cytogenetics), a Molecular Biopathology laboratory (for hereditary, infectious and oncohematology pathologies) and a central laboratory (for biochemistry, flow cytometry, immunology, pathological anatomy, hematology and microbiology).